Wednesday, Jun 30, 2004
South San Francisco, Calif. -- June 30, 2004 --Genentech, Inc. (NYSE: DNA) today announced four senior appointments in the company's Commercial Operations and Development organizations: the promotion of Martin Babler to vice president, Immunology Sales and Marketing; the appointment of Karen McCormick to vice president, Specialty Therapeutic Sales and Marketing; the promotion of Vince Anicetti to vice president, Product Portfolio Management; and the promotion of Charles Johnson to vice president, Clinical Biotherapeutics.
Immunology Sales and Marketing
Martin Babler, 39, joined Genentech in 1998 as director, Cardiovascular Marketing. During the next several years, he held positions as director and senior director of Commercial Development and senior director of Immunology Sales and Marketing.
Babler is responsible for leading the strategic direction of the Immunology commercial area, including the management of sales and marketing efforts for Xolair® (Omalizumab) and market preparation for Rituxan® (Rituximab) for immune system disorders and product line extensions. Babler will continue to report to Diane Parks, senior vice president and general manager, Specialty Biotherapeutics and Managed Care at Genentech.
"Martin has played an integral role in advancing the Immunology commercial area," said Parks. "Because of his extensive experience in the commercial organizations of the biotech and pharmaceutical industries, Martin is ideally suited to help Genentech achieve the aggressive goals required to support our growth in the immunology area."
Prior to joining Genentech, Babler held several positions of increasing responsibility at Eli Lilly and Company. He completed basic and advanced studies in pharmaceutical science and received a degree in pharmacy from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. Martin is a graduate of the Executive Development Program at the Kellogg Graduate School of Management.
Specialty Therapeutic Sales and Marketing
Karen McCormick, 49, has been appointed to vice president, Specialty Therapeutic Sales and Marketing. In this position, McCormick is responsible for leading the strategic direction of the Specialty Therapeutic area, including the management of sales and marketing activities for RAPTIVA® (efalizumab), the Nutropin® [somatropin (rDNA origin) for injection] family of products, and Pulmozyme® (dornase alfa). McCormick will report to Diane Parks, senior vice president and general manager, Specialty Biotherapeutics and Managed Care at Genentech.
"Karen brings to Genentech a proven track record of leading successful sales and marketing teams in complex and competitive environments," said Parks. "I'm confident that she will help Genentech continue to build its specialty therapeutics position, an important and promising area of Genentech's business."
McCormick joins Genentech from Lifescan, a Johnson & Johnson company, where she was vice president of the Institutional and Cardiovascular business units and a board member. McCormick also held a number of senior-level positions at other Johnson & Johnson companies, including Indigo and Janssen Pharmaceutica. Prior to those positions, McCormick worked in the sales and marketing organizations at Lederle Laboratories.
McCormick received her bachelor's degree from Kenyon College and holds a master's in business administration from the Harvard Graduate School of Business.
Product Portfolio Management
Vince Anicetti, 49, joined Genentech in 1981 as a scientific manager in the Manufacturing and Process Sciences department. Over the past 23 years, Anicetti has held a number of leadership positions in several functional areas at Genentech. In addition to working in the Manufacturing and Process Sciences department, Anicetti has held management positions in Quality, Regulatory Affairs, Product Development, and most recently, Product Portfolio Management, where he served as senior director and head of the group.
Anicetti will be responsible for leading the direction of the Product Portfolio Management group, maximizing the value of Genentech's extensive product portfolio and providing leadership and management for cross-functional teams and steering committees. Anicetti continues to report to Susan D. Hellmann, M.D., M.P.H., Genentech's president of Product Development.
"Vince has made significant contributions to Genentech throughout his tenure," said Hellmann. "His expertise and broad experience in managing the drug development system will be critical as we continue to build our product portfolio and maintain Genentech's industry leadership in bringing medicines to patients."
Prior to joining Genentech, Anicetti held positions at the Tulane Medical School in New Orleans and the Smith-Kettlewell Institute of Visual Sciences in San Francisco. He received a bachelor's degree in biology and a master's degree in clinical science from San Francisco State University.
Charles Johnson, 53, joined Genentech in 1994 and has held several leadership positions in the Development organization over the past 10 years. More recently, Johnson led the successful approvals of Xolair and RAPTIVA, playing a major role in the U.S. Food and Drug Administration's advisory committee meetings for both products.
In this role, Johnson will oversee clinical development and post-approval efforts for pipeline and marketed products in the Pulmonary, Endocrine, Dermatology, Cardiovascular, Ophthalmology, Rheumatology/Immunology, and Neurology areas. Johnson will continue to report to Hal Barron, M.D., senior vice president, Development, and chief medical officer at Genentech.
"I am confident that Charlie will continue to make significant contributions to the Development organization, drawing upon his strong clinical expertise," said Barron. "His efforts will help ensure that our pipeline translates into meaningful therapies for patients."
Prior to joining Genentech, Johnson held several positions at Washington University in St. Louis, where he was a Pulmonary Fellow and Assistant Professor, as well as director of the Cystic Fibrosis Center. Johnson received his undergraduate degree from Gresham's School, Holt, in the United Kingdom and his medical degree from the University of Cape Town in South Africa. He gained his board certification in Pediatrics at the Red Cross War Memorial Children's Hospital in Cape Town.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Eighteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 12 biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For press releases and additional information about the company, please visit http://www.gene.com.